Literature DB >> 23791364

Early biomarkers related to secondary primary cancer risk in radiotherapy treated prostate cancer patients: IMRT versus IMAT.

Joke Werbrouck1, Piet Ost, Valerie Fonteyne, Gert De Meerleer, Wilfried De Neve, Evelien Bogaert, Laurence Beels, Klaus Bacher, Anne Vral, Hubert Thierens.   

Abstract

PURPOSE: To investigate whether rotational techniques (Volumetric Modulated Arc Therapy - VMAT) are associated with a higher risk for secondary primary malignancies compared to step-and-shoot Intensity Modulated Radiation Therapy (ss-IMRT). To this end, radiation therapy (RT) induced DNA double-strand-breaks and the resulting chromosomal damage were assessed in peripheral blood T-lymphocytes of prostate cancer (PCa) patients applying γH2AX foci and G0 micronucleus (MN) assays. METHODS AND MATERIALS: The study comprised 33PCa patients. A blood sample was taken before start of therapy and after the 1st and 3rd RT fraction to determine respectively the RT-induced γH2AX foci and MN. The equivalent total body dose (D(ETB)) was calculated based on treatment planning data.
RESULTS: A linear dose response was obtained for γH2AX foci yields versus D(ETB) while MN showed a linear-quadratic dose response. Patients treated with large volume (LV) VMAT show a significantly higher level of induced γH2AX foci and MN compared to IMRT and small volume (SV) VMAT (p<0.01). Assuming a linear-quadratic relationship, a satisfactory correlation was found between both endpoints (R(2) 0.86).
CONCLUSIONS: Biomarker responses were governed by dose and irradiated volume of normal tissues. No significant differences between IMRT and rotational therapy inherent to the technique itself were observed.
Copyright © 2013 The Authors. Published by Elsevier Ireland Ltd.. All rights reserved.

Entities:  

Keywords:  IMRT; Micronuclei; Rotational radiation therapy; Secondary cancer risk; γH2AX foci

Mesh:

Substances:

Year:  2013        PMID: 23791364     DOI: 10.1016/j.radonc.2013.05.014

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  3 in total

Review 1.  Radiation-Induced Chromosomal Aberrations and Immunotherapy: Micronuclei, Cytosolic DNA, and Interferon-Production Pathway.

Authors:  Marco Durante; Silvia C Formenti
Journal:  Front Oncol       Date:  2018-05-29       Impact factor: 6.244

2.  Prognostic value of the micronucleus assay for clinical endpoints in neoadjuvant radiochemotherapy for rectal cancer.

Authors:  Tim Beißbarth; Hendrik Andreas Wolff; Leif Hendrik Dröge; Steffen Hennies; Stephan Lorenzen; Lena-Christin Conradi; Henriette Quack; Torsten Liersch; Christian Helms; Miriam Alice Frank; Markus Anton Schirmer; Margret Rave-Fränk
Journal:  BMC Cancer       Date:  2021-03-04       Impact factor: 4.430

3.  Risk and Prognosis of Secondary Rectal Cancer After Radiation Therapy for Pelvic Cancer.

Authors:  Runkun Yang; Xu Guan; Enrui Liu; Ran Wei; Zhixun Zhao; Haipeng Chen; Zheng Liu; Ming Yang; Zheng Jiang; Xishan Wang
Journal:  Front Oncol       Date:  2020-10-29       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.